BEIJING and GOTHENBURG, Sweden, Oct. 24, 2025 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for the treatment of Hepatitis D Virus...
Hence then, the article about ribo granted ema orphan drug designation for sirna therapeutic rbd1016 for hepatitis delta virus hdv infection was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection )
Also on site :
- 'We've lost our way': Clifton's operator gives up on downtown Los Angeles
- Disney World Just Dropped the Opening Date for the Muppets Rock 'n' Roller Coaster and Your Summer Plans Are Officially Set
- Disney Is Bringing Pixie Dust to the Carolinas and We Finally Have a First Look at the New Asteria Neighborhood